Drug intelligence / Profile preview

YBR-8002

Development stage: Preclinical
Lead developer: Guizhou Yibai Pharmaceutical
Modality: Small Molecules

Overview

YBR-8002 is a small molecule drug candidate being developed by Guizhou Yibai Pharmaceutical for the treatment of esophageal cancer. Categorized as a Registration Class 2 innovative drug in China, the program is currently in the preclinical stage, specifically undergoing drug-ability exploration and early development research. As of 2026, the specific molecular target and mechanism of action for YBR-8002 have not been publicly disclosed by the sponsor.

Beyond the preview

Go deeper on YBR-8002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YBR-8002.

Explore the full profile